LOS ANGELES, CA / ACCESSWIRE / August 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between November 9, 2017 and April 10, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 9, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Helius touted positive results from the clinical trial of its Portable Neuromodulation Stimulator ("PoNS") device for treatment of traumatic brain injury, but the clinical trial actually did not produce statistically significant positive results on the effectiveness of the treatment. The trial data did not support the Company’s application for regulatory clearance, and the FDA subsequently denied the application due to insufficient supporting data. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Helius, investors suffered damages. According to the Complaint, the Company made false and misleading statements to the market. Helius touted positive results from the clinical trial of its Portable Neuromodulation Stimulator ("PoNS") device for treatment of traumatic brain injury, but the clinical trial actually did not produce statistically significant positive results on the effectiveness of the treatment. The trial data did not support the Company’s application for regulatory clearance, and the FDA subsequently denied the application due to insufficient supporting data. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Helius, investors suffered damages.